betaxolol has been researched along with metoprolol in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (27.03) | 18.7374 |
| 1990's | 2 (5.41) | 18.2507 |
| 2000's | 16 (43.24) | 29.6817 |
| 2010's | 8 (21.62) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Baldwin, JJ; Christy, ME; Denny, GH; Freedman, MB; Gross, DM; Habecker, CN; Lyle, PA; Ponticello, GS; Sweet, CS; Varga, SL | 1 |
| Binet, JL; Cavero, IG; Lefèvre-Borg, F; Manoury, PM; Rousseau, J | 1 |
| Carrupt, PA; el Tayar, N; Testa, B; Van de Waterbeemd, H | 1 |
| Baldwin, JJ; Gross, DM; McClure, DE; Williams, M | 1 |
| Baldwin, JJ; Denny, GH; Freedman, MB; Gross, DM; Hirschmann, R; Ponticello, GS; Sweet, CS | 1 |
| Iakovidis, D; Jackman, GP; Louis, SN; Louis, WJ; Nero, TL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Chandrasena, G; Gavai, AV; Nayeem, A; Santone, K; Vaz, RJ | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Beaumont, K; Di, L; Maurer, TS; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Talele, TT | 1 |
| Akritopoulos, P; Petounis, AD | 1 |
| Bevan, JA; McPherson, GA | 1 |
| Nathanson, JA | 1 |
| Anlauf, M; Bock, KD; Brodde, OE; Weber, F | 1 |
| Engel, G | 1 |
| Ayaori, M; Hosoai, H; Ishikawa, T; Nakamura, H; Nishio, E; Shige, H; Suzukawa, M; Yoshida, H | 1 |
| Baldridge, WH; Baptiste, DC; Chauhan, BC; Hartwick, AT; Jollimore, CA; Kelly, ME; Tremblay, F | 1 |
| Antunes, E; Arantes, EC; Baracat, JS; De Nucci, G; Teixeira, CE | 1 |
| Dupliakov, DV; Glukhova, VL; Golovina, GA; Vozhdaeva, ZI | 1 |
| Frana, P; Rihacek, I; Soucek, M | 1 |
| Moilanen, H; Pitkänen, L; Ranta, VP; Urtti, A | 1 |
| Kardas, P | 1 |
| Liu, HM; Wang, P; Wang, XJ; Zhang, JY; Zheng, JX | 1 |
| Christodorescu, R; Filpescu, D; Iliuta, L; Moldovan, H; Radulescu, B; Vasile, R | 1 |
| Bencini, A; Chelazzi, L; Conti, L; Paoli, P; Rossi, P | 1 |
| Jia, L; Li, Z; Wu, J; Xiao, X | 1 |
| Aiglova, R; Danek, J; Gloger, V; Lazarova, M; Pavlu, L; Precek, J; Schee, A; Skala, T; Taborsky, M; Vicha, M | 1 |
2 review(s) available for betaxolol and metoprolol
| Article | Year |
|---|---|
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Models, Molecular; Receptors, Adrenergic, beta; Structure-Activity Relationship | 1988 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for betaxolol and metoprolol
| Article | Year |
|---|---|
[Cardioselective beta-adrenoblockers in patients with stable angina pectoris. Comparison of efficacy and safety].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Benzopyrans; Betaxolol; Bisoprolol; Blood Flow Velocity; Echocardiography; Ethanolamines; Exercise Tolerance; Female; Follow-Up Studies; Humans; Male; Metoprolol; Middle Aged; Myocardial Contraction; Nebivolol; Treatment Outcome | 2006 |
A comparison of the trough-to-peak ratio of cardio-selective beta-blockers in patients with newly diagnosed hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Betaxolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Delayed-Action Preparations; Female; Humans; Hypertension; Male; Metoprolol; Prospective Studies; Time Factors | 2006 |
Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Betaxolol; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Metoprolol; Middle Aged; Patient Compliance; Quality of Life; Treatment Outcome | 2007 |
Prevention of perioperative atrial fibrillation with betablockers in coronary surgery: betaxolol versus metoprolol.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Betaxolol; Cardiopulmonary Bypass; Coronary Artery Bypass; Cost-Benefit Analysis; Drug Costs; Female; Hospital Costs; Hospital Mortality; Humans; Immobilization; Length of Stay; Male; Metoprolol; Middle Aged; Patient Compliance; Perioperative Care; Quality of Life; Romania; Time Factors; Treatment Outcome | 2009 |
31 other study(ies) available for betaxolol and metoprolol
| Article | Year |
|---|---|
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted amino)-2-hydroxypropoxy]phenyl]imidazole class. 2.
Topics: Adrenergic beta-Antagonists; Animals; Female; Guinea Pigs; Heart Rate; Hydrogen Bonding; Imidazoles; In Vitro Techniques; Receptors, Adrenergic, beta; Solubility; Structure-Activity Relationship | 1986 |
Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Antihypertensive Agents; Betaxolol; Biotransformation; Cardiovascular Diseases; Chronic Disease; Female; Guinea Pigs; In Vitro Techniques; Kinetics; Male; Propanolamines; Rana esculenta; Rats; Structure-Activity Relationship | 1987 |
Use of (S)-(trifloxymethyl)oxirane in the synthesis of a chiral beta-adrenoceptor antagonist, (R)- and (S)-9-[[3-(tert-butylamino)-2-hydroxypropyl]oximino]fluorene.
Topics: Adrenergic beta-Antagonists; Animals; Binding, Competitive; Chemical Phenomena; Chemistry; Dihydroalprenolol; Female; Guinea Pigs; Indicators and Reagents; Lung; Muscle Contraction; Muscle, Smooth, Vascular; Myocardium; Propanolamines; Stereoisomerism | 1982 |
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class.
Topics: Adrenergic alpha-Agonists; Animals; Female; Guinea Pigs; Heart; Imidazoles; Indicators and Reagents; Isoproterenol; Magnetic Resonance Spectroscopy; Receptors, Adrenergic; Receptors, Adrenergic, beta; Structure-Activity Relationship | 1983 |
LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; CHO Cells; Cricetinae; Cyclopropanes; Female; Humans; Imidazoles; In Vitro Techniques; Ligands; Phenoxypropanolamines; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Trachea; Urea | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series.
Topics: Animals; Cytochrome P-450 CYP2D6 Inhibitors; Humans; Inhibitory Concentration 50; Models, Molecular; Propanolamines; Quantitative Structure-Activity Relationship; Substrate Specificity | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Volume of Distribution in Drug Design.
Topics: Drug Design; Half-Life; Pharmacokinetics | 2015 |
The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.
Topics: Animals; Cyclopropanes; Drug Discovery; Humans; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Pharmacology | 2016 |
Influence of topical and systemic beta-blockers on tear production.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Animals; Betaxolol; Butoxamine; Drug Administration Routes; Injections, Intramuscular; Lacrimal Apparatus; Male; Metoprolol; Oxprenolol; Propanolamines; Propranolol; Rabbits; Time Factors; Timolol | 1989 |
Specialization in beta-1 and beta-2 adrenoceptor distribution in veins of the rabbit face: relationship to myogenic tone and sympathetic nerve innervation.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Betaxolol; Catechols; Electrophysiology; Face; Isoproterenol; Male; Metoprolol; Propanolamines; Propranolol; Rabbits; Receptors, Adrenergic, beta; Sympathetic Nervous System; Tetrodotoxin; Veins | 1987 |
Stereospecificity of beta adrenergic antagonists: R-enantiomers show increased selectivity for beta-2 receptors in ciliary process.
Topics: Adenylyl Cyclases; Adrenergic beta-Antagonists; Animals; Betaxolol; Ciliary Body; Heart; Isoproterenol; Male; Metoprolol; Myocardium; Propanolamines; Rabbits; Receptors, Adrenergic, beta; Stereoisomerism; Structure-Activity Relationship; Timolol | 1988 |
Subclassification of human beta-adrenergic receptors mediating renin release.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Betaxolol; Dobutamine; Fenoterol; Humans; In Vitro Techniques; Isoproterenol; Male; Metoprolol; Propanolamines; Propranolol; Receptors, Adrenergic; Receptors, Adrenergic, beta; Renin | 1983 |
Subclasses of beta-adrenoceptors--a quantitative estimation of beta 1- and beta 2- adrenoceptors in guinea pig and human lung.
Topics: Aged; Animals; Atenolol; Betaxolol; Cell Membrane; Guinea Pigs; Humans; Iodocyanopindolol; Lung; Metoprolol; Middle Aged; Models, Biological; Pindolol; Practolol; Propanolamines; Receptors, Adrenergic; Receptors, Adrenergic, beta | 1981 |
Effects of beta-blockers on HMG CoA reductase and LDL receptor activity in cultured human skin fibroblasts.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Betaxolol; Cells, Cultured; Fibroblasts; Humans; Hydroxymethylglutaryl CoA Reductases; Lipoproteins, LDL; Male; Metoprolol; Propranolol; Receptors, LDL | 1996 |
Comparison of the neuroprotective effects of adrenoceptor drugs in retinal cell culture and intact retina.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Betaxolol; Brimonidine Tartrate; Calcium; Cell Culture Techniques; Cell Survival; Dose-Response Relationship, Drug; Fura-2; Glutamic Acid; Metoprolol; N-Methylaspartate; Neuroglia; Neuroprotective Agents; Quinoxalines; Rats; Rats, Long-Evans; Retina; Retinal Ganglion Cells; Timolol | 2002 |
Effects of beta-adrenoceptor antagonists in the neural nitric oxide release induced by electrical field stimulation and sodium channel activators in the rabbit corpus cavernosum.
Topics: Aconitine; Adrenergic beta-Antagonists; Animals; Atenolol; Betaxolol; Binding Sites; Electric Stimulation; In Vitro Techniques; Insect Proteins; Male; Metoprolol; Muscle Relaxation; Neurotoxins; Nitric Oxide; Penis; Propanolamines; Propranolol; Rabbits; Saxitoxin; Scorpion Venoms; Sodium Channel Agonists; Tetrodotoxin; Veratridine | 2005 |
Binding of betaxolol, metoprolol and oligonucleotides to synthetic and bovine ocular melanin, and prediction of drug binding to melanin in human choroid-retinal pigment epithelium.
Topics: Adrenergic beta-Antagonists; Animals; Betaxolol; Cattle; Choroid; Humans; Melanins; Metoprolol; Oligonucleotides; Pigment Epithelium of Eye | 2007 |
Application of kinetic resolution using HCS as chiral auxiliary: novel synthesis of beta-blockers (S)-betaxolol and (S)-metoprolol.
Topics: Adrenergic beta-Antagonists; Betaxolol; Kinetics; Metoprolol; Molecular Structure; Stereoisomerism | 2009 |
The solid-state structure of the β-blocker metoprolol: a combined experimental and in silico investigation.
Topics: Adrenergic beta-1 Receptor Antagonists; Betaxolol; Calorimetry, Differential Scanning; Computer Simulation; Crystallography, X-Ray; Databases, Chemical; Hydrogen Bonding; Metoprolol; Molecular Dynamics Simulation; Molecular Structure; Powder Diffraction | 2019 |
Enantioseparation of chiral β-blockers using polynorepinephrine-coated nanoparticles and chiral capillary electrophoresis.
Topics: Adrenergic beta-Antagonists; Betaxolol; Carteolol; Electrophoresis, Capillary; Equipment Design; Humans; Limit of Detection; Magnetics; Magnetite Nanoparticles; Metoprolol; Norepinephrine; Solid Phase Microextraction; Stereoisomerism | 2019 |
Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.
Topics: Adrenergic beta-Antagonists; Betaxolol; Bisoprolol; Carbazoles; Carvedilol; Czech Republic; Heart Failure; Humans; Metoprolol; Nebivolol; Propanolamines; Retrospective Studies | 2021 |